Background: Surrogate markers have been identified to play significant role in the pathogenesis and prognosis of HIV infection. However, there is limited data on the utility of neopterin estimation in HIV infection. Therefore, the study sought to measure and ascertains the trends of serum neopterin and other biochemical parameters as indicators of predicting HIV disease progression and treatment response among HIV seropositive individuals. Kwantwi et al.; JAMMR, 29(3): 1-10, 2019; Article no.JAMMR.38580 2 Methods: A cross-sectional study with 298 HIV seropositive individuals consisting of 165 HIV on highly active antiretroviral treatment and 136 naïve highly active antiretroviral patients. Venous blood was drawn for the assay of neopterin and the other biochemical parameters. Results: Neopterin was significantly lower (P<0.0001) in patients in the highly active antiretroviral therapy than those in the naïve highly active antiretroviral therapy group. Serum neopterin increased as the disease progresses and decreased as the duration of the therapy treatment increased (p=0.0001). At a cut of point of 54.5 nmol/L, neopterin gave a sensitivity of 97.5%, specificity of 95.9% and an area under the curve of 0.99. Conclusion: Neopterin has shown to be to be good marker in predicting HIV disease progression especially in patients with CD4 counts less than 200mm -3 and a useful indicator of patient's response to therapy treatment.
INTRODUCTION
HIV infection has been a challenge to the medical fraternity in the last three decades [1] . The use of HAART in the treatment of HIV infection has also resulted in a number of adverse effects [2, 3] , hence the necessity of clinical assessment of the impact of HAART in the management of people living with HIV infection.
Several studies have shown the value of prognostic markers such as CD4 counts, viral RNA loads and soluble markers of immune activation in predicting HIV disease progression [4, 5] but the principal biomarker used in the monitoring of HIV infected individuals is the CD4 count. However, CD4 counts estimation is relatively expensive and require considerable skills as compared to other soluble biomarkers. In resource-limited settings, clinical monitoring of patients are difficult owing to the huge expenses associated with CD4 count test [6] [7] [8] . Considering the fact that HIV infection is mostly endemic in poor developing/third world countries where resources and infrastructures are limited, there is the need for cost effective, easily performed and readily available surrogate markers that can assist in predicting the disease progression and patient's response to HAART.
A major feature of HIV infection is the activation of all component of the immune system and an increased production of several surrogate cytokines, which are indications of immunologic changes in the body during HIV infection. However, the limitation in the ability to measure circulating cytokines has led to the determination of products of immune activation which reflect cytokine activity [9] . Such assessment includes soluble biomarkers and one such candidate marker is neopterin. Neopterin is a metabolite of guanosine triphosphate produced by macrophages and dendritic cells upon activation of gamma interferon. It is considered as a marker of immune activation and correlate with the disease progression [7, 10] .
As neopterin levels reflect the degree of immune deficiency in HIV-positive patients, and perhaps the response to ART, the question of whether neopterin has (as claimed elsewhere) [11, 12] , prognostic value concerning the HIV disease progression is eminent. It was against this premise that we evaluated serum neopterin and other biochemical parameters among HIV seropositive individuals on HAART and HAART naïve groups in other to ascertain the trends of these markers in HIV disease progression.
MATERIALS AND METHODS

Study Design
This was a cross sectional study carried out in the ART clinic of the Bomso Specialist hospital in the Ashanti region of Ghana from August 2015 to March 2016.
Study Population
Non-probability sampling technique was used to recruit 298 confirmed HIV seropositive individuals consisting of 162 HIV HAART patients and 136 HIV HAART naïve patients. Patients who were confirmed HIV seropositive and were 18 and above were recruited into the study. Patients with co-infection such hepatitis B, C, tuberculosis and pregnant women were excluded from the study. All participants were placed into three groups according to the center for disease control classification based on CD4 lymphocytes of patients. The groups were; CD4 counts less than 200 mm -3 , CD4 count between 200 and 499 mm -3 and the third group consisted of patients with CD4 above 500 mm -3 .
Data Collection and Laboratory Analysis
A well-structured questionnaire was used to obtain demographic and clinical characteristics from the patients. 5ml of venous blood was taken from each patient under sterile conditions after a tourniquet has been applied for less than a minute. 2 ml out of the blood taken was place in an anti-coagulated sequestrene bottles-EDTA for CD4 and CD3 analysis using the Becton Dickenson and company haematological analyzer called the BD FACS Count from California in USA. The remaining blood was centrifuged after they have been made to clot in a plain test tube. The serum obtained was stored at -20°C for the assay of neopterin (ELISA) and the other biochemical parameters using an autoanalyzer known as ATAC® 8000 Random Chemistry System from USA by Elan Diagnostic System.
Data Analysis
All the analysis were performed with the statistical package for social sciences version 20. The data were presented as median interquartile range (IQR) for non-parametric variables whiles grouped variables were expressed as proportions. Comparison between HAART naïve and HAART patients were determined with the use of Mann Whitney U test. Spearman correlation rank test was used to determine the correlations between variables. A suitable cut off point was determined for neopterin using the Youden's index. The performance of neopterin was assessed using the area under the curve from the receiver operator characteristics. Pvalue < 0.05 was considered as statistically significant.
RESULTS
The socio-demographic and clinical characteristics of the studied population are shown in Table  1 . Out of the two hundred and ninety eight (298) participants, there were more females than male for both the HAART (70.2%) and the HAART naïve patients (69.3%). There was no statistically significance difference between the age of the HAART and HAART naïve group (p=0.203). ). None of the studied participants had a history of smoking and alcohol intake. There was no incidence of therapy discontinuation among the HAART group [ Table 1 ]. Table 2 shows the comparison of biochemical parameters of the HAART and HAART naïve groups. Serum neopterin of the HAART naïve group (51.70 nmol/L) was significant higher (p=0.0001) than the HAART group (26.40 nmol/L). Serum albumin was significantly higher in the HAART group than the HAART naïve group (p=0.0001) whereas all the other biochemical parameters were significantly lower (p=0.0001) in the HAART group compared to the HAART naïve group.
Among the HAART group, patients on Tenofovir, Lamivudine and Nevirapine combination had the lowest mean serum levels of 27.7 nmol/L whereas patients on Zidovudine, Lamivudine and Nevirapine combination had the highest mean serum neopterin levels of 45. nmol/L [ Fig. 1 ]. Table 3 shows the comparison of the biochemical parameters with the respective CD4 counts in the HAART and HAART naïve group. Neopterin increased as the disease progresses as measured by the respective CD4 counts in both the HAART and the HAART naïve groups. Elevated neopterin values were found in patients whose CD4 counts were below 200 mm -3 whereas of neopterin lowest values were found in patients with CD4 counts ≥ 500 mm -3 in both the HAART (17.20 nmol/L) and the HAART naïve groups (21.40 nmol/L). All the biochemical parameters except albumin also increased as the disease progresses. Table 4 shows correlation of neopterin with CD4, biochemical parameters and some clinical factors. A significant negative correlation was observed between neopterin and CD4 count for both HAART (r= -0.99, p=0.0001) and HAART naïve patients (r= -0.96, p=0.0001). We observed a significant negative correlation between serum neopterin and albumin, BMI and the duration of therapy treatment for both the HAART and the HAART naïve groups. All the other biochemical parameters had a significant positive correlation with neopterin significantly except urea, which did not show any significant correlation with serum neopterin in the HAART naïve group. Fig. 2 shows the duration on HAART and serum neopterin levels among the HAART group. Neopterin levels decreased as the duration of HAART increased. Table 5 shows the predictive performance of serum neopterin in predicting CD4 counts <200 mm -3 . The diagnostic accuracy of serum neopterin in predicting CD4 less than 200 mm -3 was found to be 83.9% . At cut off point of 55.4 nmol/L, the sensitivity and specificity were found to be 97.5% and 95.9% respectively for the total participants. The area under the curve were also 0.99,1.0 and 0.98 for the total subject, HAART and HAART naïve groups repectively. From Fig. 2 , neopterin levels were also found to be decreased as the duration of the therapy increased with patients being on the therapy for more than four years having the lowest serum neopterin levels (24.20 nmol/L) followed by those who have been on the therapy between two and four years (28.90 nmol/L). Highest neopterin values were found in patients who have been on the therapy for less than two years (32.80 nmol/L).On the contrary CD4 count increased as the duration on the therapy increased. 
correlation coefficient, BMI-Body mass index, DT -duration of HAART treatment
DISCUSSION
Serum albumin levels in the HAART group was appreciably higher than the HAART naïve group (P<0.0001). Albumin levels decreased as the disease progressed. These findings tie with earlier reports [13, 14] . Low albumin levels may be explained by poor nutritional status .Other Also since the concentrations of acute phase protein are decreased in chronic inflammation as a result of elevation in cytokines level which imposes the liver to channel other proteins needed for immune responses, it was not surprising that albumin levels were decreased as the infection progressed given the fact that albumin is a negative acute phase protein. serum globulin levels of the HAART naïve were significantly higher than the HAART experienced group. Consistent with this study, other previous cross sectional studies that have evaluated serum globulins have found reduction in serum globulin in HAART groups compared to HAART naïve groups [15, 16] . Serum globulins increased as the disease progressed. T observation could be attributed to the chronic immune activation and B cell dysfunction which induces hypergamaglobulinemia via polyclonal B 
6
HAART types and their mean serum neopterin levels
Duration on HAART and serum neopterin levels among the HAART patients possible mechanisms for decreased albumin levels may be attributed to the persistent inflammatory response caused by the infection. Also since the concentrations of acute phase chronic inflammation as a result of elevation in cytokines level which imposes the liver to channel other proteins , it was not surprising that albumin levels were decreased as the infection progressed given the fact that is a negative acute phase protein. The serum globulin levels of the HAART naïve group were significantly higher than the HAART . Consistent with this study, other previous cross sectional studies that have ound reduction s compared to . Serum globulins increased as the disease progressed. This observation could be attributed to the chronic immune activation and B cell dysfunction which induces hypergamaglobulinemia via polyclonal B cell activation leading to a spontaneous increase in immunoglobulins which may result in the elevation of serum globulin in the HAART naïve group [17] Both AST and ALT of the HAART naïve group were higher than the HAART This is consistent with earlier findings by Osakunor, C Obirikorang, V Fianu, I Asare and M Dakorah [18] and inconsistent with Ngala et al and Lucien et al. [2, 19] .
There was no statistical difference in the body mass index of the HAART and HAART naïve groups (P=0.502). BMI was found to correlate positively with CD4 count for both the HAART and HAART naïve groups. Concurrent with finding, previous study have reported higher BMI to be associated with increased CD4 counts as well as improved immune reconstitution and survival that could resulting in a slower disease progression [20] [21] [22] [23] . The strong positive correlation between BMI and CD4 count is an indication that increased BMI may be associated ; Article no.JAMMR.38580 levels among the HAART patients cell activation leading to a spontaneous increase in immunoglobulins which may result in the globulin in the HAART naïve Both AST and ALT of the HAART were higher than the HAART group. This is consistent with earlier findings by DNM C Obirikorang, V Fianu, I Asare and M and inconsistent with Ngala et al
There was no statistical difference in the body mass index of the HAART and HAART naïve (P=0.502). BMI was found to correlate positively with CD4 count for both the HAART . Concurrent with this finding, previous study have reported higher BMI to be associated with increased CD4 counts as constitution and survival that could resulting in a slower disease . The strong positive correlation between BMI and CD4 count is an may be associated with immunological improvement and a reduction in both immune activations that can contribute to a decrease in serum neopterin levels. In support of this, this study found serum neopterin to correlate negatively with CD4 count for both the HAART and the HAART naïve groups.
Serum neopterin levels were significantly lower in patients who were on the highly active antiretroviral therapy than the naïve highly active antiretroviral patients (P<0.0001). This result correlates well with studies by Bipath et al. [24] and N Amirayan-Chevillard, H Tissot-Dupont, Y Obadia, H Gallais, JL Mege and C Capo [25] who indicated that HAART significantly decrease circulating levels of neopterin by 30% (61.7 nmol/L and 88.1 nmol/L for HAART and HAART naïve respectively). HIV infection is associated with a continuous immune activation which stimulates the release of inflammatory cytokines by increasing the total level of neopterin in the HAART naïve group. Several explanations could be attributed to the increased immune activation seen in HIV infection. At the site of HIV infection, there is migration of tissue peripheral CD4 cells which results in the activation of macrophages. This leads to a reduction in the peripheral blood CD4 cells which contributes to a persistent immune activation. Neopterin levels were found to be increased as the disease progressed with higher median values in patients with CD4 counts <200 mm -3 . This result is in line with studies by S Chadha, P Bhalla, H Gautam, A Chakravarti, S Saini, S Anuradha and R Dewan [7] who also reported higher neopterin values in patients with CD4 counts less than 200mm -3 . This elevation could be due to the stimulatory role of γ IFN in the synthesis of neopterin [26] and the link between chronic elevation of γ IFN and HIV disease progression [12] . D Mildvan, J Spritzler, SE Grossberg, JL Fahey, DM Johnston, BR Schock and J Kagan [10] also reported that elevated baseline neopterin levels are linked with increased risk of HIV disease progression as well as the predictive value of neopterin in the disease progression.
Among the HAART group, we observed a significant positive correlation between CD4 and duration on therapy (rho 0.297, p=0.002) whereas a negative significant correlation was observed between the duration on therapy and neopterin (rho -0.289, p=0.003). This is an indication that increased duration on HAART may result in an increase in CD4 and a decline in serum neopterin levels. This results is backed by earlier studies conducted by Bipath et al. [11] .
Several mechanisms have been proposed for the effect of these therapies on serum neopterin levels of patients infected with HIV. In a randomized doubled blind study aimed at evaluating the effect of HAART treatment on the human immunodeficiency virus, AC Collier, RW Coombs, DA Schoenfeld, RL Bassett, J Timpone, A Baruch, M Jones, K Facey, C Whitacre, VJ McAuliffe, et al. [27] found an association between HAART and an increase in the CD4 T lymphocyte cells and a decline in markers of immune activation; which promotes a partial recovery in functions of the immune cells. This was consistent with the results that CD4 count increased among HAART group than the HAART naive group and a decrease in neopterin levels among the HAART group. In another cross sectional study, the functions of the lymphoid progenitor cells including the differentiation into the B and T lymphocytes have also been shown to normalize among HIV patients treated with HAART [28] . HAART has been shown to induce changes in the T helper 1 and T helper 2 which differentiate to produce cytotoxic T cells and antibodies respectively [29] and also reverses the defects in the CD4 cells [30] . The cumulative effect of these mechanisms of HAART on the immune cells is the restoration of interleukin 2 productions that modulate various aspect of the immune response [31] and a decline in the level of cytokines involved in the pathogenesis of HIV infection. Consequently there is a reduction in the immune activation and the circulating levels of serum neopterin in HIV infected individuals [12] . Although HAART was associated with a decrease in serum neopterin levels, the usage of Tenofovir, Lamivudine and Nevirapine combination resulted in a much more decrease in serum neopterin levels compared with the other HAART combinations used in this study.
CONCLUSION
Neopterin levels were elevated in HAART naïve group compared to HAART group. Increased neopterin levels were associated with a decline in CD4 count and correlated with severity of the disease progression whereas longer duration on the therapy was associated with an increase in CD4 count and a decline in neopterin levels. The results of this study has revealed that neopterin can be a useful biomarker in predicting HIV disease progression especially in patients with CD4 counts less than 200mm -3 and a useful indicator of patient's response to therapy treatment. Regular measurement of serum neopterin and other biochemical parameters could provide some prognostic information on the disease progression to enhance close monitoring and therapeutic interventions for individuals with a greater possibility of progressing with the disease in resource limited settings.
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